Cognitive enhancing agents in schizophrenia and bipolar disorder

Annabel Vreeker, Annet H. van Bergen, René S. Kahn

PII: S0924-977X(15)00117-0
DOI: http://dx.doi.org/10.1016/j.euroneuro.2015.04.014
Reference: NEUPSY11018

To appear in: European Neuropsychopharmacology

Received date: 7 December 2014
Accepted date: 10 April 2015

Cite this article as: Annabel Vreeker, Annet H. van Bergen, René S. Kahn, Cognitive enhancing agents in schizophrenia and bipolar disorder, European Neuropsychopharmacology, http://dx.doi.org/10.1016/j.euroneuro.2015.04.014

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Cognitive enhancing agents in schizophrenia and bipolar disorder

Annabel Vreeker*a, Annet H. van Bergen*a, René S. Kahn*

*aequal contribution

1University Medical Center Utrecht, Department of Psychiatry, Brain Center Rudolf Magnus, The Netherlands

Corresponding author: René S. Kahn, MD, PhD, Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Heidelberglaan 100, 3508 GA Utrecht, PO box 85500, tel: 0031887556025, fax: 0031887555443 (R.Kahn@umcutrecht.nl)

Key words: schizophrenia, bipolar disorder, cognition, cognitive impairment, pharmacology, drug development
Number of tables: 2
Word count: 5,480

Summary

Cognitive dysfunction is a core feature of schizophrenia and is also present in bipolar disorder (BD). Whereas decreased intelligence precedes the onset of psychosis and remains relatively stable thereafter; high intelligence is a risk factor for bipolar illness but cognitive function decreases after onset of symptoms. While in schizophrenia, many studies have been conducted on the development of cognitive enhancing agents, in BD such studies are almost non-existent. This review focuses on the pharmacological agents with putative effects on cognition in both schizophrenia and bipolar illness; specifically agents targeting the dopaminergic, cholinergic and glutamatergic neurotransmitter pathways in schizophrenia and the cognitive effects of lithium, anticonvulsants and antipsychotics in BD. In the final analysis we conclude that cognitive enhancing agents have not yet been produced convincingly for schizophrenia and have hardly been studied in BD. Importantly, studies should focus on other phases of the illness. To be able to treat cognitive deficits effectively in schizophrenia, patients in the very early stages of the illness, or even before – in the ultra-high risk stages – should be targeted. In contrast, cognitive deficits occur later in BD, and therefore drugs should be tested in BD after the onset of illness. Hopefully, we will then find effective drugs for the incapacitating effects of cognitive deficits in these patients.
دریافت فوری متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات